Chemistry:SDB-006
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H24N2O |
| Molar mass | 320.436 g·mol−1 |
| 3D model (JSmol) | |
| |
SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 19 nM for human CB2 receptors, and 134 nM for human CB1 receptors.[1][2] It was discovered during research into the related compound SDB-001 which had been sold illicitly as "2NE1".[3] SDB-006 metabolism has been described in literature.[4]
See also
References
- ↑ "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience 6 (8): 1445–58. August 2015. doi:10.1021/acschemneuro.5b00107. PMID 25921407. https://zenodo.org/record/47750.
- ↑ "The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs". Drug Testing and Analysis 10 (7): 1099–1109. January 2018. doi:10.1002/dta.2362. PMID 29350472.
- ↑ "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience 4 (7): 1081–92. July 2013. doi:10.1021/cn400035r. PMID 23551277.
- ↑ "In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry". Forensic Toxicology 35 (2): 252–262. July 2017. doi:10.1007/s11419-016-0350-9.
 |  |
